

SCHEDULE OF INVESTMENTS

March 29, 2018

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.6%					
BIOTECHNOLOGY - 71.2%					
Amgen, Inc.	94,995	\$ 16,194,749			
Gilead Sciences, Inc.	196,920	14,845,799			
Celgene Corp.*	139,473	12,442,386			
Biogen, Inc.*	42,078	11,521,798			
Vertex Pharmaceuticals, Inc.*	58,729	9,571,652			
Regeneron Pharmaceuticals, Inc.*	27,479	9,462,668			
Illumina, Inc.*	37,513	8,868,823			
Alexion Pharmaceuticals, Inc.*	64,956	7,239,996			
Incyte Corp.*	73,325	6,110,172			
BioMarin Pharmaceutical, Inc.*	70,900	5,747,863			
Alnylam Pharmaceuticals, Inc.*	42,402	5,050,078			
Seattle Genetics, Inc.*	81,287	4,254,562			
Bio-Rad Laboratories, Inc. — Class A*	16,072	4,019,286			
Sage Therapeutics, Inc.*	24,830	3,999,368			
Bluebird Bio, Inc.*	22,722	3,879,782			
Exelixis, Inc.*	170,017	3,765,877			
United Therapeutics Corp.*	29,936	3,363,609			
Ionis Pharmaceuticals, Inc.*	75,281	3,318,386			
Prothena Corporation plc*	89,117	3,271,485			
Avexis, Inc.*	25,340	3,131,517			
Exact Sciences Corp.*	74,514	3,005,150			
Blueprint Medicines Corp.*	32,180	2,950,906			
Ligand Pharmaceuticals, Inc. — Class B*	16,965	2,801,939			
FibroGen, Inc.*	59,720	2,759,064			
Loxo Oncology, Inc.*	23,610	2,723,886			
Amicus Therapeutics, Inc.* ¹	173,211	2,605,093			
Spark Therapeutics, Inc.*	38,020	2,531,752			
Halozyme Therapeutics, Inc.*	128,894	2,525,033			
ACADIA Pharmaceuticals, Inc.*	108,543	2,438,961			
Ultragenyx Pharmaceutical, Inc.*	46,966	2,394,796			
Medicines Co.* ¹	71,448	2,353,497			
AnaptysBio, Inc.* ¹	22,570	2,349,086			
Puma Biotechnology, Inc.* ¹	33,420	2,274,231			
Immunomedics, Inc.*	151,420	2,212,246			
Myriad Genetics, Inc.*	71,636	2,116,844			
Esperion Therapeutics, Inc.*	29,047	2,100,970			
Radius Health, Inc.* ¹	55,313	1,987,949			
Insmed, Inc.*	83,620	1,883,122			
Spectrum Pharmaceuticals, Inc.*	114,740	1,846,167			
Dynavax Technologies Corp.*	91,700	1,820,245			
ImmunoGen, Inc.*	168,190	1,769,359			
Sangamo Therapeutics, Inc.*	88,540	1,682,260			
Editas Medicine, Inc.*	50,450	1,672,418			
PTC Therapeutics, Inc.*	58,950	1,595,187			
Acorda Therapeutics, Inc.*	66,171	1,564,944			
AMAG Pharmaceuticals, Inc.* ¹	63,071	1,270,881			
Intercept Pharmaceuticals, Inc.* ¹	8,200	504,464			
Total Biotechnology		<u>197,800,306</u>			
PHARMACEUTICALS - 23.7%					
AbbVie, Inc.	178,478	16,892,943			
Nektar Therapeutics*	59,627	6,335,965			
Alkermes plc*	69,048	4,002,022			
Neurocrine Biosciences, Inc.*	48,091	3,988,187			
Jazz Pharmaceuticals plc*	24,830	\$ 3,749,082			
PRA Health Sciences, Inc.*	41,088	3,408,660			
Sarepta Therapeutics, Inc.*	45,720	3,387,395			
Agios Pharmaceuticals, Inc.*	40,424	3,305,875			
Array BioPharma, Inc.*	165,930	2,707,977			
TESARO, Inc.* ¹	43,773	2,501,189			
Ironwood Pharmaceuticals, Inc. — Class A*	153,881	2,374,384			
Clovis Oncology, Inc.*	44,127	2,329,906			
Horizon Pharma plc*	158,224	2,246,781			
Global Blood Therapeutics, Inc.*	46,235	2,233,150			
Portola Pharmaceuticals, Inc.*	63,805	2,083,871			
Pacira Pharmaceuticals, Inc.*	55,279	1,721,941			
Eagle Pharmaceuticals, Inc.* ¹	24,830	1,308,293			
Flexion Therapeutics, Inc.* ¹	58,020	1,300,228			
Total Pharmaceuticals		<u>65,877,849</u>			
HEALTHCARE-PRODUCTS - 2.5%					
Bio-Techne Corp.	24,762	3,740,052			
QIAGEN N.V.*	99,463	3,213,650			
Total Healthcare-Products		<u>6,953,702</u>			
HEALTHCARE-SERVICES - 2.2%					
Charles River Laboratories International, Inc.*	31,438	3,355,692			
Syneos Health, Inc.*	76,010	2,698,355			
Total Healthcare-Services		<u>6,054,047</u>			
Total Common Stocks					
(Cost \$154,146,884)					<u>276,685,904</u>
RIGHTS^{†††} - 0.0%					
Chelsea Therapeutics International* ²	231,107	—			
Dyax Corp.* ²	167,165	—			
Clinical Data, Inc.* ²	24,000	—			
Total Rights		—			<u>—</u>
(Cost \$17,304)					
				FACE	
				AMOUNT	
REPURCHASE AGREEMENTS^{†††,3} - 0.6%					
JPMorgan Chase & Co.					
issued 03/29/18 at 1.80%					
due 04/02/18	\$ 1,317,451	1,317,451			
Bank of America Merrill Lynch					
issued 03/29/18 at 1.78%					
due 04/02/18	431,105	431,105			
Total Repurchase Agreements		<u>1,748,556</u>			
(Cost \$1,748,556)					

BIOTECHNOLOGY FUND

	SHARES	VALUE
SECURITIES LENDING COLLATERAL^{†,4} - 3.9%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 1.49% ⁵	10,830,439	<u>\$ 10,830,439</u>
Total Securities Lending Collateral (Cost \$10,830,439)		<u>10,830,439</u>
Total Investments - 104.1% (Cost \$166,743,183)		<u>\$ 289,264,899</u>
Other Assets & Liabilities, net - (4.1)%		<u>(11,322,648)</u>
Total Net Assets - 100.0%		<u>\$ 277,942,251</u>

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

¹ All or portion of this security is on loan at March 29, 2018.

² Security was fair valued by the valuation committee at March 29, 2018. The total value of fair valued securities amounts to \$0, (cost \$17,304) or less than 0.01% of total net assets.

³ Repurchase Agreements.

⁴ Securities lending collateral.

⁵ Rate indicated is the 7 day yield as of March 29, 2018.

plc — Public Limited Company